Literature DB >> 11850842

Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping.

Olivier Bluteau1, Jean-Christophe Beaudoin, Patricia Pasturaud, Jacques Belghiti, Dominique Franco, Paulette Bioulac-Sage, Pierre Laurent-Puig, Jessica Zucman-Rossi.   

Abstract

One of the most frequent deletions in hepatocellular carcinoma (HCC) is that involving the long arm of chromosome 4 (30 to 70% of the cases). These chromosomal deletions are closely related to hepatitis B virus (HBV) infection. A tumor suppressor gene (TSG) located on 4q has been proposed in liver carcinogenesis, but has not been identified as yet. Despite previous LOH studies focused on 4q in HCC, a clear minimal common region of deletion (MCRD) could not be delimited. To further investigate the role of chromosome 4q LOH in the pathogenesis of HCC, 85 microsatellite markers spanning chromosome 4q were systematically analysed in a series of 154 well-characterized primary liver tumors. In 59 tumors (38%), LOHs were observed for at least two adjacent markers. Analysis of 31 tumors demonstrating a partial or interstitial 4q deletion allowed to define three MCRDs of 15, 9 and 8 Mb at the 4q22, 4q34 and 4q35 regions, respectively. Seven putative candidate genes located in 4q22, DAPP1, BMPR1B, PKD2, HERC3, SMARCAD1, CEB1 and ENH were screened for mutations but no somatic alterations were identified. Search for relationships between the specific regions of deletion and clinical parameters showed a significant association between loss of the 4q34-35 region with alcohol intake (P=0.005) and with high grade of differentiation (P=0.02). These results are in contrast with the close association between HBV infection and the whole 4q LOH and reveal heterogeneity of 4q LOH in relation to different risk factors. In the light of these new findings, which link different 4q LOH regions to different etiologic factors, the molecular mechanisms underlying 4q deletions in HCC and the targeted gene(s) remain to be identified.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850842     DOI: 10.1038/sj.onc.1205197

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Genomic shotgun array: a procedure linking large-scale DNA sequencing with regional transcript mapping.

Authors:  Ling-Hui Li; Jian-Chiuan Li; Yung-Feng Lin; Chung-Yen Lin; Chung-Yung Chen; Shih-Feng Tsai
Journal:  Nucleic Acids Res       Date:  2004-02-11       Impact factor: 16.971

2.  A mortality gene(s) for the human adenocarcinoma line HeLa maps to a 130-kb region of human chromosome 4q22-q23.

Authors:  Steven D Bryce; Vivienne Morrison; Nicola J Craig; Nicholas R Forsyth; Sara A Fitzsimmons; Hazel Ireland; Andrew P Cuthbert; Robert F Newbold; E Kenneth Parkinson
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

3.  Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.

Authors:  Debasmita Roy; Sang-Hoon Sin; Blossom Damania; Dirk P Dittmer
Journal:  Blood       Date:  2011-06-17       Impact factor: 22.113

4.  Tumor suppress genes screening analysis on 4q in sporadic colorectal carcinoma.

Authors:  Li-Xin Jiang; Jie Xu; Zhao-Wen Wang; Da-Peng Li; Zhi-Hai Peng; Jian-Jun Gao; Lin He; Hai-Tao Zheng
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

5.  The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations.

Authors:  Xavier Bisteau; Matias J Caldez; Philipp Kaldis
Journal:  Cancers (Basel)       Date:  2014-01-13       Impact factor: 6.639

6.  Hepatocyte Nuclear Factor 1α-Mutated Hepatocellular Adenomas: An Atypical Presentation.

Authors:  Camila Maria Neves Sousa; Patricia Maria Miranda Gadelha; Rafaella de Sousa Cartaxo; George Washington Holanda Pedrosa; Rodrigo Schuler Honorio; José Milton de Castro Lima; Gustavo Rêgo Coelho; Clovis Rêgo Coelho
Journal:  Case Rep Gastroenterol       Date:  2017-10-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.